Study Evaluating the Safety and Effectiveness of the FLEXUS(TM) Interspinous Spacer

May 31, 2018 updated by: Globus Medical Inc

A Prospective Randomized Clinical Investigation of the FLEXUS(TM) Interspinous Spacer: A Pivotal Study

The purpose of this investigation is to evaluate the safety and effectiveness of the FLEXUS™ Interspinous Spacer as compared to the XSTOP® Spacer for the treatment of patients who are suffering from lumbar spinal stenosis at one or two contiguous levels.

Study Overview

Study Type

Interventional

Enrollment (Actual)

215

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Denver, Colorado, United States, 80124
        • Skyridge Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Lumbar spinal stenosis as defined by leg, buttock or groin pain, with or without back pain, that relieves during flexion, with radiographic confirmation of spinal stenosis by CT or MRI scans at one or two contiguous levels between L1 and S1. If back pain is also present, it must be partially relieved during flexion
  • Narrowing of the spinal canal, nerve root canal or intervertebral foramen at one or two levels
  • Able to sit for 50 minutes without pain
  • Able to walk 50 feet or more
  • Age 50 years or over
  • Has completed at least 6 months of conservative treatment
  • Has a Zurich Claudication Questionnaire (ZCQ) score of ≥ 1.5 for Physical Function (PF) and ≥ 1.5 for Symptom Severity (SS)
  • Other as specified in the approved protocol

Exclusion Criteria:

  • Cannot sit for 50 minutes without pain
  • Cannot walk for more than 50 feet
  • Unremitting pain in any spinal position
  • Axial back pain only without leg, buttock, or groin pain
  • Fixed motor deficit
  • Cauda equine syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retension or incontinence) dysfunction
  • Severe symptomatic lumbar spinal stenosis at more than two levels
  • Significant instability of the lumbar spine
  • Has had any surgery of the lumbar spine
  • Morbid obesity defined as a body mass index >40 or a weight more than 100 lbs over ideal body weight
  • Active systemic disease such as AIDS, HIV, Hepatitis, etc.
  • Active systemic or local infection
  • Angina, active rheumatoid arthritis, advanced diabetes or any other systemic disease that would affect the subject's welfare or outcome of the study
  • Osteoporosis, defined as DEXA bone density measured T-score < -2.5
  • Spinal metastasis to the vertebrae
  • Known allergy to device materials titanium, tantalum, or polyetheretherketone (PEEK) polymer
  • Other as specified in approved protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FLEXUS™ Interspinous Spacer
Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
Active Comparator: XSTOP® Interspinous Spacer
Treatment of lumbar spinal stenosis with the XSTOP® Spacer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Less Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Score
Time Frame: 24 months

Change in the Zurich Claudication Questionnaire (ZCQ) score at 24 months compared with the score at baseline as follows:

  • Change of >0.5 points in Physical Function on a scale of 1-4 points (lower values are considered a better outcome)
  • Change of >0.5 points in Symptom Severity on a scale of 1-5 points (lower values are considered a better outcome)
  • Satisfaction of <2.5 points on a scale of 1-4 points (lower values are considered a better outcome) The Zurich Claudication Questionnaire is a three part form that quantifies severity of symptoms, physical function characteristics, and patient's satisfaction after treatment.
24 months
Number of Participants With a Successful Neurologic Status
Time Frame: 24 months

Neurological status is based on four types of measurement parameters: motor, sensory, reflexes, and special assessments. Each parameter will be coded as follows:

Motor 0 Total Paralysis

  1. Palpable or Visible Contraction
  2. Active Movement, Gravity Eliminated
  3. Active Movement, Against Gravity
  4. Active Movement, Against Some Resistance
  5. Active Movement, Against Full Resistance

Sensory 0 Absent

  1. Impaired
  2. Normal

Reflexes 0 Absent or Trace

  1. Hyper-reflexic
  2. Normal or hypo-reflexic

Straight Leg Raise 0 0°-70° (abnormal)

1 >70°-90° (normal)

If all evaluations for the parameter are determined to be normal, then the parameter is given a normal status. If any evaluations for the parameter are abnormal, then the parameter is given an abnormal status. The overall neurological status will be considered a success if and only if all the four parameters are stable or improved.

24 months
Number of Participants With no Additional Surgery for Lumbar Spinal Stenosis at the Spinal Level That Was Treated
Time Frame: 24 months
Measures the number of participants who did not have another surgery for treatment of lumbar spinal stenosis at the same spinal level that was originally treated. Data, including adverse events, were monitored, evaluated and assessed for evidence of additional surgical treatment at the spinal level that was originally treated.
24 months
Number of Participants With an Absence of Implant-related Complications
Time Frame: 24 months

Absence of implant-related complications, including device dislodgement, defined as:

  • Failure of implant material (e.g. fracture);
  • Implant migration outside of the interspinous space (posteriorly beyond the posterior margin of the spinous processes, anteriorly within the spinal canal, or laterally more than half of the implant width); or
  • Other complications that can be specifically associated with the implanted device.
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Oswestry Disability Index (ODI) at 24 Months
Time Frame: 24 months
The Oswestry Disability Index (ODI) questionnaire contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel. Each topic is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. The subject chooses the statement which most closely resembles their situation. Each question is scored on a scale of 0-5 with the first statement being zero and indicating the least amount of disability and the last statement is scored 5 indicating most severe disability. Scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability.
24 months
Mean Visual Analog Scale (VAS) - Back Pain at 24 Months
Time Frame: 24 months
The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with "no pain" on the left border and "as severe as it could be" on the right border. The subject is instructed to make a mark along the line to represent the intensity of back pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.
24 months
Mean Visual Analog Scale (VAS) - Right Leg Pain at 24 Months
Time Frame: 24 months
The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with "no pain" on the left border and "as severe as it could be" on the right border. The subject is instructed to make a mark along the line to represent the intensity of right leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.
24 months
Mean Visual Analog Scale (VAS) - Left Leg Pain at 24 Months
Time Frame: 24 months
The visual analog scale (VAS) is a questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with "no pain" on the left border and "as severe as it could be" on the right border. The subject is instructed to make a mark along the line to represent the intensity of left leg pain currently being experienced; 0mm is equal to no pain and 100mm is pain as severe as it could be. The clinician records the distance of the mark in millimeters from the left end of the scale.
24 months
Change of Quality of Life
Time Frame: 24 months
Change in mental or physical composite score of the short form SF36
24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2008

Primary Completion (Actual)

July 1, 2015

Study Completion (Actual)

July 1, 2015

Study Registration Dates

First Submitted

July 1, 2010

First Submitted That Met QC Criteria

July 2, 2010

First Posted (Estimate)

July 5, 2010

Study Record Updates

Last Update Posted (Actual)

June 1, 2018

Last Update Submitted That Met QC Criteria

May 31, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Spinal Stenosis

Clinical Trials on FLEXUS(TM) Interspinous Spacer

Subscribe